Recro Pharma, Inc. (NASDAQ:REPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

Several other research firms have also recently issued reports on REPH. Piper Jaffray Companies set a $11.00 price objective on Recro Pharma and gave the stock a “buy” rating in a research report on Tuesday, July 25th. Roth Capital set a $20.00 target price on Recro Pharma and gave the company a “buy” rating in a research report on Monday, July 31st. Finally, Janney Montgomery Scott cut Recro Pharma from a “buy” rating to a “fair value” rating and decreased their target price for the company from $21.00 to $6.50 in a research report on Wednesday, June 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $12.63.

Shares of Recro Pharma (NASDAQ:REPH) opened at 8.72 on Wednesday. The firm’s market cap is $166.19 million. The firm has a 50-day moving average price of $8.14 and a 200 day moving average price of $7.72. Recro Pharma has a one year low of $5.81 and a one year high of $10.17.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.06. The business had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.90 million. Recro Pharma had a negative return on equity of 56.04% and a negative net margin of 46.75%. On average, analysts forecast that Recro Pharma will post ($2.35) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/11/recro-pharma-inc-reph-lowered-to-sell-at-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently made changes to their positions in REPH. Marshall Wace North America L.P. acquired a new stake in shares of Recro Pharma in the 1st quarter valued at about $1,601,000. MARSHALL WACE ASIA Ltd acquired a new stake in shares of Recro Pharma in the 1st quarter valued at about $1,601,000. OxFORD Asset Management LLP boosted its position in shares of Recro Pharma by 364.3% in the 2nd quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock valued at $1,430,000 after purchasing an additional 159,619 shares during the period. State Street Corp acquired a new stake in shares of Recro Pharma in the 2nd quarter valued at about $1,047,000. Finally, Northern Trust Corp boosted its position in shares of Recro Pharma by 428.5% in the 2nd quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after purchasing an additional 144,676 shares during the period. 65.06% of the stock is owned by hedge funds and other institutional investors.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.